FORM D

SECUI

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM D

MAY 2 3 2007 NOTICE OF SALE OF SECURITIES
PURSUANT TO REGULATION D
SECTION 4(6), AND/OR

85 UNIFORM LIMITED OFFERING EXEMPTION

OMB APPROVAL

OMB Number:

3235-0076

Expires:

April 30, 2008

Estimated average burden

hours per response

1.00

SEC USE ONLY								
Serial								
ECEIVED								

Name of Offering (check if this is an amendment and name has changed, and indicate Common stock and warrants	
Filing Under (Check box(es) that apply): Rule 504 [] Rule 505 [X] Rule 506 [] Sect	tion 4(6) [] ULOE PROCESSED
Type of Filing: [] New Filing [X] Amendment	. (/ HIN 0.7 2007
A. BASIC IDENTIFICATION DATA	
1. Enter the information requested about the issuer	THOMSON
Name of Issuer ([check if this is an amendment and name has changed, and indicate ImmunoCellular Therapeutics, Ltd.	e change.)
Address of Executive Offices (Number and Street, City, State, Zip Code) 1999 Avenue of the Stars, 11th Floor, Los Angeles, California 90067	Telephone Number (Including Area Code) (310) 789-1213
Address of Principal Business Operations (Number and Street, City, State, Zip Code) (if different from Executive Offices) Same	Telephone Number (Including Area Code) Same
Brief Description of Business Development of cellular therapies	
Type of Business Organization [X] corporation [] business trust [] limited partnership, already formed [] limited partnership, to be formed	other (please specify):
Actual or Estimated Date of Incorporation or Organization: [0] 3 [8 [7] Jurisdiction of Incorporation or Organization: (Enter two-letter U.S. Postal Service al	

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR230.501 et seq. or 15 U.S.C. 77d(6).

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer, and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State:

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.



A.	BASIC	IDENTIFIC	ATION	DATA
----	-------	-----------	-------	------

2. Enter the information requested for the following:

Each promoter of the issuer, if the issuer has been organized within the past five years; • Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer; Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and Each general and managing partner of partnership issuers. [] Promoter [X] Beneficial Owner [] Executive Officer [X] Director [] General and/or Managing Partner Check Box(es) that Apply: Full Name (Last name first, if individual) Mosk, Dr. Manfred Business or Residence Address (Number and Street, City, State, Zip Code) 1999 Avenue of the Stars, 11th Floor, Los Angeles, California 90067 Check Box(es) that Apply: [] Promoter [] Beneficial Owner [X] Executive Officer [] Director [] General and/or Managing Partner Full Name (Last name first, if individual) Wohlberg, David Business or Residence Address (Number and Street, City, State, Zip Code) 1999 Avenue of the Stars, 11th Floor, Los Angeles, California 90067 [] Promoter [X] Beneficial Owner [] Executive Officer [X] Director [] General and/or Managing Partner Check Box(es) that Apply: Full Name (Last name first, if individual) Hillsberg, Sanford J. Business or Residence Address (Number and Street, City, State, Zip Code) 1999 Avenue of the Stars, 11th Floor, Los Angeles, California 90067 Check Box(es) that Apply: [] Promoter [X] Beneficial Owner [] Executive Officer [X] Director [] General and/or Managing Partner Full Name (Last name first, if individual) Yu, Dr. John Business or Residence Address (Number and Street, City, State, Zip Code) 1999 Avenue of the Stars, 11th Floor, Los Angeles, California 90067 [] Promoter [] Beneficial Owner [] Executive Officer [X] Director [] General and/or Managing Partner Check Box(es) that Apply: Full Name (Last name first, if individual) Nisi, Dr. Rudolph (Number and Street, City, State, Zip Code) Business or Residence Address 1999 Avenue of the Stars, 11th Floor, Los Angeles, California 90067 Check Box(es) that Apply: [] Promoter [] Beneficial Owner [] Executive Officer [X] Director [] General and/or Managing Partner Full Name (Last name first, if individual) Martuza, Dr. Robert Business or Residence Address (Number and Street, City, State, Zip Code) 1999 Avenue of the Stars, 11th Floor, Los Angeles, California 90067 [] Promoter [] Beneficial Owner [X] Executive Officer [] Director [] General and/or Managing Partner Check Box(es) that Apply: Full Name (Last name first, if individual) Peacock, C. Kirk Business or Residence Address (Number and Street, City, State, Zip Code) 1999 Avenue of the Stars, 11th Floor, Los Angeles, California 90067 [] Promoter [] Beneficial Owner [] Executive Officer [X] Director [] General and/or Managing Partner Check Box(es) that Apply: Full Name (Last name first, if individual) Brandwynne, Jacqueline Business or Residence Address (Number and Street, City, State, Zip Code) 1999 Avenue of the Stars, 11th Floor, Los Angeles, California 90067 [] Promoter [X] Beneficial Owner [] Executive Officer [] Director [] General and/or Managing Partner Check Box(es) that Apply: Black, Dr. Keith 8631 West Third Street, Los Angeles, California 90048

				B. II	NFORMA	TION A	BOUT OFF	ERING				
1. Has the	issuer sold	or does the	issuer inte	nd to sell to	о пол-яссте	dited inves	tors in this of	fering?				Yes No
i. Hus inc	133401 3014,	01 4005 411	o issuer mice	•			mn 2, if filing	_		***************************************		[] [13]
2. What is	the minimu	m investm	ent that will				-					\$ N/A
					-							Yes No
	٠.	•	•	•								[X]
simil is an brok	ar remunera associated i	tion for so person or a If more th	licitation of gent of a br ian five (5)	purchasers oker or dea persons to	in connecti iler registere	on with sal	aid or given, les of securiti SEC and/or I persons of s	es in the off with a state	ering. If a or states,	person to b list the name	e listed e of the	
Full Name Olian, Jr.,	(Last name : Irwin,	first, if indi	vidual)									
	Residence , 650 West (Canada		- <u>.</u>	V		
Name of A	ssociated Br		aler /A									
States in W (Check	hich Person "All States"	Listed Has or check is	s Solicited on Individual St	r Intends to ates)	Solicit Pur	chasers						[] All States
[AL] [IL] [MT] [RI]	[AK] X [IN] [NE] X [SC]	[IA]	[AR] [KS] [NH] [TN]	[CA] [KY] [NJ] [TX]	[CO] [LA] [NM] 2 [UT]	[CT] [ME] K [NY] [VT]	[DE] [MD] [NC] [VA] X	[DC] X [MA] X [ND] [WA]		[GA] [MN] [OK] X ([WI]	[HI] [MS] [OR] [WY]	[ID] [MO] [PA] [PR]
Full Name Gray, Gera	(Last name i ld E.	first, if indi	vidual)	·								
	Residence . ulting Ltd,4						E 1B5 Canac	la				
Name of A	ssociated Br		aler /A									
	hich Person "All States"											[] All States
[AL] (IL] [MT] [RI]	[IN]	X [AZ] [IA] X [NV] [SD]	[AR] [KS] [NH] [TN]	[CA] [KY] [NJ] [TX]	[CO] [LA] [NM] ? [UT]	[CT] [ME] ([NY] [VT]	[DE] [MD] [NC] [VA] X	[DC] X [MA] X [ND] [WA]	[MI] [OH]	[GA] [MN] [OK] X X [WI]	[HI] [MS] [OR] [WY]	[ID] [MO] [PA] [PR]
Full Name Haeusler, F	(Last name : Rene	first, if indi	vidual)									
	Residence . ternational !											
Name of A	ssociated Br		aler /A									
	hich Person "All States"											[] All States
[AL] [IL] [MT] [RI]	[AK] [IN] [NE] [SC]	[AZ] [IA] [NV] [SD]	[AR] [KS] [NH] [TN]	[CA] [KY] [NJ] [TX]	[CO] [LA] [NM] [UT]	[CT] [ME] [NY] [VT]	[DE] [MD] [NC] [VA]	[DC] [MA] [ND] [WA]	[FL] [MI] [OH] [WV]	[GA] [MN] [OK] [WI]	[HI] [MS] [OR] [WY]	[ID] [MO] [PA] [PR]

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

1.	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box [] and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.	Aggregate Offering Price	Amount Already Sold
	Type of Security	,	-
	Debt	\$	\$
	Equity (Units of Common Stock and Warrants)	\$ <u>6,000,000</u>	\$ 3,797,405
	[X] Common [] Preferred		
	Convertible Securities (including warrants)	\$	\$
	Partnership Interests	\$	\$
	Other (Specify	\$	\$
	Total	\$ <u>6,000,000</u>	\$ 3,797,405
2.	Answer also in Appendix, Column 3, if filing under ULOE Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."	Number Investors	Aggregate Dollar Amount of Purchases
	Accredited Investors	88	\$ <u>3,797,405</u>
	Non-accredited Investors	0	\$
	Total (for filings under Rule 504 only)		\$
	Answer also in Appendix, Column 4, if filing under ULOE		
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities of this offering. Classify securities by type listed in Part C - Question 1.	Type of Security	Dollar Amount Sold
	Type of offering		
	Rule 505	_	\$
	Regulation A		\$
	Rule 504		\$
	Total		\$
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fees	[X]	\$ 4,500
	Printing and Engraving Costs	[]	
	Legal Fees	[X]	•
	Accounting Fees	[]	
	Engineering Fees	[]	
	Sales Commissions (specify finders' fees separately)	[]	
	Other Expenses (identify) (Reimbursement of broker's expenses) finder's fee	[]	
	Wire fund expenses	[]	
	Total	[X]	l \$ <u>333,412</u>

	C. OFFERING PRICE, NUMBER OF INVESTORS, EXP	ENSE	S AND USE OF P	ROCEE	บร
P	Enter the difference between the aggregate offering price given in response to Part C - Question 1 and total expenses furnished in response to Part C - Question.a. This difference is the "adjusted gross proceeds to the issuer."				\$_3,463,993_
p	Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed to be used for each of the purposes shown. If the amount for any purpose is not known, furnish an estimate and check the box to the left of the stimate. The total of payments listed must equal the adjusted gross proceeds to be issuer set forth in response to Part C - Question 4.b above.				
			Payments to Officers, Directors, & Affiliates		Payments To Others
	Salaries and fees	[]	\$	_ []	\$
	Purchase of real estate	[]	\$	_ []	\$
	Purchase, rental or leasing and installation of machinery and equipment	[]	\$	_ []	\$
	Construction or leasing of plant buildings and facilities	[]	\$	_ []	\$
	Acquisition of other business (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger)	[]	\$	_ []	\$
	Repayment of indebtedness	[]	\$	_ []	\$
	Working capital	[]	\$	[X]	\$ <u>3,463,993</u>
	Other(specify):	[]	\$	_ []	\$
		[]	\$	_ []	\$
	Column Totals	[]	\$	_ []	\$
	Total Payments Listed (column totals added)			[X]	\$3,463,993

signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Comminformation furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502.

Issuer (Print or Type)	Signature	Date
ImmunoCellular Therapeutics, Ltd.		5-21-07
Name of Signer (Print or Type)	Title of Signer (Print or Type)	
David Wohlberg	President	

ATTENTION

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001).

E.	α			α	\sim	1 4 5	r) T	IRE.
-	•	Α.	ι μ	`	1 T N	1 🕰		IK H

1.	Is any party described in 17 CFR 230.262(c), (d), (e) or (f) presently subject to any of the disqualification provisions	Y	es	N	lo
	of such rule?	[]	[X	.]

See Appendix, Column 5, for state response.

- 2. The undersigned issuer hereby undertakes to furnish to any state administrator of any state in which this notice is filed, a notice on Form D (17 CFR 239.500) at such times as required by state law.
- 3. The undersigned issuer hereby undertakes to furnish to the state administrators, upon written request, information furnished by the issuer to offerees.
- 4. The undersigned issuer represents that the issuer is familiar with the conditions that must be satisfied to be entitled to the Uniform Limited Offering Exemption (ULOE) of the state in which this notice is filed and understands that the issuer claiming the availability of this exemption has the burden of establishing that these conditions have been satisfied.

The issuer has read this notification and knows the contents to be true and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

Issuer (Print or Type)	Signature	Date
ImmunoCellular Therapeutics, Ltd.	0-4-0-1	5-21-07
Name of Signer (Print or Type)	Title of Signer (Print or Type)	
David Wohlberg	President	

Print the name and title of the signing representative under his signature for the state portion of this form. One copy of every notice on Form D must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

			· · · · · · · · · · · · · · · · · · ·	APPEN	NDIX				
1	Intend to non-a	1 to sell accredited is in State 1-Item 1)	Type of Security and aggregate offering price offered in state (Part C-Item 1) 4 Type of investor and amount purchased in State (Part C-Item 2)						
State	Yes	No		Number of Accredited Investors	Amount	Number of Non- Accredited Investors	Amount	Yes	ation of granted) -Item 1)
AL									<u>_</u>
AK	,								
AZ			Common Stock & Warrants	1	\$105,000				
AR		!							
CA									
СО									
СТ			Common Stock & Warrants	1	22,500				
DE									
DC									
FL			Common Stock & Warrants	1	75,000				
GA									
HI									
ID									
IL									
IN									
IA									
KS									
KY									
LA		ļ.							
ME				•					
MD				. <u></u>					
MA									
MI			Common Stock & Warrants	1	200,001				
MN									
MS									
МО									
MT									
NE		<u> </u>							

	· · · · · · · · · · · · · · · · · · ·			APPEN	NDIX						
1	Intend to sell to non-accredited investors in State (Part B-Item 1)		Type of Security and aggregate offering price offered in state (Part C-Item 1)	4 Type of investor and amount purchased in State (Part C-Item 2)			turity Type of investor and amount purchased in State tate (Part C-Item 2)			under Sta (if ye explai waiver	5 diffication ate ULOE s, attach nation of granted) 3-Item 1)
State	Yes	No		Number of Accredited Investors	Amount	Number of Non- Accredited Investors	Amount	Yes	No		
NV			Common Stock & Warrants	1	100,000						
NH											
NJ											
NM											
NY			Common Stock & Warrants	3	\$243,502						
NC									·		
ND											
ОН											
OK											
OR			Common Stock & Warrants	1	\$25,500						
PA											
RI											
SC											
SD											
TN											
TX											
UT											
VT									,		
VA											
WA			Common Stock & Warrants	1	\$450,000						
WV											
WI			Common Stock & Warrants	1	\$150,000						
WY	Ì										
PR											

Other: 77 foreign investors for \$2,425,902

